enGene Therapeutics Inc. (ENGNW)Montreal, Canada | NasdaqCM
0.23 USD
-0.02
(-7.668%) ⇩
(Aug. 28, 2026, 2:43 p.m.
EDT)
|
Hot Take ↕ | Aug. 22, 2026, 1:23 a.m. EDT
The immediate outlook is severely bearish as the stock trades at its 52-week low, having recently collapsed from $2.23 to $0.43 in less than a month, signaling a complete loss of momentum and liquidity. Fundamentally, the business is deteriorating rapidly with negative returns on both assets and equity, massive free cash burn, and a balance sheet that relies entirely on cash reserves rather than organic growth or profitability. There is no dividend to provide income, and the lack of analyst coverage combined with a 'NO MODEL' status for short-term forecasting suggests the market has effectively abandoned the security. This is a clear sell signal driven by both technical breakdown and fundamental insolvency. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 13.07 |
| Beta | -0.28 |
| Previous Name | enGene Holdings Inc. |
| Website | https://www.engene.com |
| Attribute | Value |
|---|---|
| Address1 | 4,868 Rue Levy |
| Address2 | Suite 220 |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | -0.277 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | 3.809 |
| City | Montreal |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.23 |
| Current Ratio | 12.567 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.2681 |
| Day Low | 0.23 |
| Debt To Equity | 13.07 |
| Display Name | enGene Therapeutics |
| Ebitda | -131,911,000 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.2681 |
| Fifty Two Week High Change | -0.03809999 |
| Fifty Two Week High Change Percent | -0.14211112 |
| Fifty Two Week Low | 0.23 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.23 - 0.2681 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 32,731,053 |
| Free Cashflow | -69,263,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 81 |
| Fullday Change | -0.019099995 |
| Fullday Change Percent | -7.667602 |
| Fullday Price | 0.23 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,023-11-01 |
| Language | en-US |
| Long Business Summary | enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada. |
| Long Name | enGene Therapeutics Inc. |
| Market | us_market |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9516520 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -126,850,000 |
| Open | 2.1 |
| Operating Cashflow | -109,997,000 |
| Operating Margins | 0.0 |
| Phone | 514 332 4888 |
| Prev Name | enGene Holdings Inc. |
| Previous Close | 0.2491 |
| Price Hint | 4 |
| Price To Book | 0.060383305 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.166 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.019099995 |
| Regular Market Change Percent | -7.667602 |
| Regular Market Day High | 0.2681 |
| Regular Market Day Low | 0.23 |
| Regular Market Day Range | 0.23 - 0.2681 |
| Regular Market Open | 2.1 |
| Regular Market Previous Close | 0.2491 |
| Regular Market Price | 0.23 |
| Regular Market Time | 1,787,942,586 |
| Regular Market Volume | 36,009 |
| Return On Assets | -0.28863 |
| Return On Equity | -0.52585 |
| Sand P52 Week Change | 0.20504117 |
| Sector | |
| Sector Key | |
| Short Name | enGene Holdings Inc. Warrants |
| Source Interval | 15 |
| State | QC |
| Symbol | ENGNW |
| Total Cash | 258,464,992 |
| Total Cash Per Share | 3.858 |
| Total Debt | 33,351,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 36,009 |
| Website | https://www.engene.com |
| Zip | H4R 2P1 |